First-Line Treatment of Lambert-Eaton Myasthenic Syndrome
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder that requires prompt immunotherapeutic management. First-line treatment combines a foundational immunosuppressant with a steroid-sparing agent to control disease activity while minimising long-term corticosteroid exposure.
Treatment Approach
The standard first-line strategy involves glucocorticosteroid therapy dosed according to disease severity, used for the shortest effective duration, in combination with a steroid-sparing immunosuppressant. The regimen is introduced gradually over several weeks under regular laboratory monitoring.
Complete dosing schedule, titration steps, and the full monitoring protocol are detailed in the structured evidence-based regimen.
Key Monitoring Target
During immunosuppressant therapy, a critical laboratory goal is achieving and maintaining the target range:
Absolute lymphocyte count 600–1,000 /μl
References
DOI: 10.1177/17562864231213240
- GKS must be used for the treatment of LEMS as a basic immunotherapeutic agent at a dosage appropriate to the severity of the disease for as short a period as possible, taking into account comorbidities, contraindications, and side effects.
- AZA must be used for steroid-sparing therapy.
- As with MG, based on expert knowledge, the recommendation is to initially start a combination therapy of GKS and AZA.
- The specific recommendations for dosing and therapy monitoring are analogous to MG.
- The therapy should be started with 25–50 mg daily in the first week and then gradually increased over 3–4 weeks under regular laboratory control.
- An absolute lymphocyte count of 600–1000/μl is targeted during therapy.
View source ↗